Abstract
Prostate cancer was one of the first cancer types where FDA (Food and Drug Administration) approval was granted to a cancer vaccine, sipuleucel-T, in the metastatic setting for asymptomatic or minimally symptomatic patients. This marked the beginning of the era of immunotherapies in cancer and stimulated the interest to develop other immune-based novel agents. In addition to sipuleucel-T vaccine, pox viral-based vaccine and personalized peptide vaccine are also being investigated in prostate cancer. Other agents that modulate the tumor microenvironment to enhance the immune response against the prostate cancer cells is also being developed. Immune checkpoint inhibitors such as ipilimumab, anti-PD-1 monoclonal antibody (programmed cell death-1), and Indoleamine 2,3-dioxygenase (IDO) inhibitors have shown some promise in this field. However, similar to sipuleucel-T vaccine, the preliminary data reflects the efficacy of these to be limited to mCRPC patients with favorable risk factors without any visceral disease. More clinical trials are needed to identify the group of patients with mCRPC that would benefit from immunotherapy. In this article we review the role of immune-based therapies including vaccines and immune checkpoint inhibitors in mCRPC.
Keywords: Castration resistant prostate cancer, sipuleucel-T, PROSTVAC-VF, personalized peptide vaccines, ipilimumab, Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) inhibitor, Indoleamine 2, 3-dioxygenase (IDO), PD-1 targeted immunotherapy.
Graphical Abstract
Current Molecular Pharmacology
Title:A New Era of Immunotherapy in Prostate Cancer
Volume: 9
Author(s): Christopher Pizzola, Syed M. Rizvi and Monika Joshi
Affiliation:
Keywords: Castration resistant prostate cancer, sipuleucel-T, PROSTVAC-VF, personalized peptide vaccines, ipilimumab, Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) inhibitor, Indoleamine 2, 3-dioxygenase (IDO), PD-1 targeted immunotherapy.
Abstract: Prostate cancer was one of the first cancer types where FDA (Food and Drug Administration) approval was granted to a cancer vaccine, sipuleucel-T, in the metastatic setting for asymptomatic or minimally symptomatic patients. This marked the beginning of the era of immunotherapies in cancer and stimulated the interest to develop other immune-based novel agents. In addition to sipuleucel-T vaccine, pox viral-based vaccine and personalized peptide vaccine are also being investigated in prostate cancer. Other agents that modulate the tumor microenvironment to enhance the immune response against the prostate cancer cells is also being developed. Immune checkpoint inhibitors such as ipilimumab, anti-PD-1 monoclonal antibody (programmed cell death-1), and Indoleamine 2,3-dioxygenase (IDO) inhibitors have shown some promise in this field. However, similar to sipuleucel-T vaccine, the preliminary data reflects the efficacy of these to be limited to mCRPC patients with favorable risk factors without any visceral disease. More clinical trials are needed to identify the group of patients with mCRPC that would benefit from immunotherapy. In this article we review the role of immune-based therapies including vaccines and immune checkpoint inhibitors in mCRPC.
Export Options
About this article
Cite this article as:
Pizzola Christopher, Rizvi M. Syed and Joshi Monika, A New Era of Immunotherapy in Prostate Cancer, Current Molecular Pharmacology 2016; 9 (3) . https://dx.doi.org/10.2174/1874467208666150716120551
DOI https://dx.doi.org/10.2174/1874467208666150716120551 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biodistribution and Dosimetry of 177Lu-tetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
Current Radiopharmaceuticals p53 Regulation of Energy Metabolism and Mitochondria Regulation of p53 in Cancer Cells: An Insight into the Role of Manganese Superoxide Dismutase
Current Pharmaceutical Biotechnology Bee Venom: Its Potential Use in Alternative Medicine
Anti-Infective Agents Antitumor Activity of Oxali-Titanocene Y in Xenografted CAKI-1 Tumors in Mice
Letters in Drug Design & Discovery Oridonin, a Promising Antitumor Natural Product in the Chemotherapy of Hematological Malignancies
Current Pharmaceutical Biotechnology Rhenium-188 and Copper-67 Radiopharmaceuticals for the Treatment of Bladder Cancer
Mini-Reviews in Medicinal Chemistry Oncolytic Viruses Driven by Tumor-Specific Promoters
Current Cancer Drug Targets Doxycycline in Mitochondrial Mediated Pathway of Apoptosis: A Systematic Review
Anti-Cancer Agents in Medicinal Chemistry Molecular Mapping and Docking Interactions for Selective Anti-Fertility Potency of Estrogen Analogs
Letters in Drug Design & Discovery Effect-based Hazard Identification of House Dust by In Vitro Assays Detecting Dioxin-like Compounds, Thyroid and Reproductive Toxicants
Current Organic Chemistry Computerized Tomography (CT) Updates and Challenges in Diagnosis of Bone Metastases During Prostate Cancer
Current Medical Imaging Polysaccharide Colloids as Smart Vehicles in Cancer Therapy
Current Pharmaceutical Design Molecular Surgery with Auger Electron-Emitting Radiopharmaceuticals
Current Radiopharmaceuticals The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Current Pharmaceutical Design Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Synthesis of New Dihydroquinopimaric Acid Analogs with Nitrile Groups as Apoptosis-Inducing Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry A Dual Role of Cyclin E in Cell Proliferation and Apotosis May Provide a Target for Cancer Therapy
Current Cancer Drug Targets Scheduling of Taxanes: A Review
Current Clinical Pharmacology miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets